Kymera director sells 12,000 shares from options
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kymera Therapeutics director Elena Ridloff exercised stock options covering 12,000 shares of common stock at an exercise price of $14.18 per share, then sold 12,000 shares in open-market transactions at weighted average prices around $85–$86 under a pre-arranged Rule 10b5-1 trading plan, leaving no directly held common shares reported.
Insider Trade Summary 10b5-1
Exercise and Sale: 12,000 shares ($855K approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Ridloff Elena
Role
Director
Sold
12,000 shs ($1.02M)
Approx. gross sale proceeds
$1.02M
Approx. exercise cost
$170K
Approx. pre-tax spread
$855K
Share of Position Sold
100%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,600 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,600 | $14.18 | $65K |
| Sale | Common Stock | 3,400 | $85.1946 | $290K |
| Sale | Common Stock | 1,200 | $86.05 | $103K |
| Exercise | Stock Option (Right to Buy) | 7,400 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,400 | $14.18 | $105K |
| Sale | Common Stock | 7,400 | $85.3701 | $632K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 12,000 to 0 contracts (Direct);
Common Stock, 0 to 0 shares (Direct)
Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (4)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The shares underlying this stock option are fully vested and exercisable.
Key Figures
Options exercised: 12,000 shares at $14.18/share
Shares sold: 12,000 shares
Sale price (weighted avg 1): $85.3701 per share
+3 more
6 metrics
Options exercised
12,000 shares at $14.18/share
Stock option exercises converting into common stock
Shares sold
12,000 shares
Total common shares sold across reported transactions
Sale price (weighted avg 1)
$85.3701 per share
Common stock open-market sale on 2026-03-31
Sale price (weighted avg 2)
$85.1946 per share
Common stock open-market sale on 2026-04-01
Sale price (weighted avg 3)
$86.0500 per share
Additional common stock sale on 2026-04-01
Post-transaction direct holdings
0 shares
Total_shares_following_transaction on final reported sale
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested and exercisable financial
"The shares underlying this stock option are fully vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Kymera Therapeutics (KYMR) disclose for Elena Ridloff?
Kymera reported that director Elena Ridloff exercised stock options for 12,000 common shares at $14.18 per share and sold 12,000 shares in open-market trades around $85–$86 per share, fully disposing of the exercised shares.
Were Kymera Therapeutics (KYMR) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated December 11, 2025. Such plans pre-arrange trade timing and size, indicating the reported sales followed a preset schedule rather than discretionary market timing.
At what prices did the Kymera Therapeutics (KYMR) insider sales occur?
Shares were sold in multiple trades at weighted average prices of $85.37, $85.19, and $86.05 per share. Footnotes explain each average reflects numerous trades within narrow price ranges, and detailed breakdowns are available upon request.
What net effect did the Form 4 transactions have on Kymera Therapeutics (KYMR) insider ownership?
The transactions show an exercise-and-sell pattern: 12,000 shares acquired via option exercise and 12,000 shares sold. The transaction summary reports 12,000 shares exercised, 12,000 shares sold, and a net-sell direction, resulting in no directly held shares remaining from these grants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
